医学
内科学
慢性肝炎
抗病毒治疗
疾病
免疫学
病毒
作者
Danqing Hu,Peng Wang,Xiaojing Wang,Xue Hu,Da Huang,Weiming Yan,Dong Xi,Meifang Han,Qin Ning,Hongwu Wang
标识
DOI:10.1016/j.jfma.2023.12.001
摘要
Approximately one third of CHB + NAFLD patients were non-obese. Non-obese patients, while less metabolically abnormal, had a similar risk for fibrosis progression as obese patients. Obesity status did not impact the efficiency of antiviral therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI